Study finds a decline of 2 g/dL or more in hemoglobin after starting oral anticoagulants may signal occult cancer, particularly gastrointestinal malignancies
A significant decline in hemoglobin levels after starting oral anticoagulation may be associated with an increased risk of newly diagnosed cancer among patients with atrial fibrillation, even in the absence of clinically apparent bleeding, according to a recent study.
Researchers found that patients experiencing a hemoglobin decline of 2 g/dL or more had a higher incidence of cancer compared with those who did not experience a significant decrease. The association was particularly pronounced for gastrointestinal cancers, suggesting that unexplained hemoglobin reduction following initiation of anticoagulant therapy may warrant further clinical evaluation.
The study was conducted using data from the Korean National Health Insurance Service database and was published in JACC: CardioOncology by Pil-Sung Y. and colleagues.
Study Included Nearly 6,800 Patients With Atrial Fibrillation
Researchers analyzed national health registry data involving 6,789 patients with atrial fibrillation who started oral anticoagulant therapy and underwent serial health assessments within one year before and after treatment initiation.
Patients with a previous history of cancer, end-stage renal disease, clinically evident bleeding, or those who discontinued anticoagulant therapy shortly after initiation were excluded from the analysis.
Participants were subsequently categorized according to changes in hemoglobin levels. One group included patients whose hemoglobin decreased by 2 g/dL or more, while the other included patients without a significant hemoglobin decline.
Significant Hemoglobin Decline Associated With Higher Cancer Incidence
Patients who experienced a hemoglobin reduction of at least 2 g/dL had an overall cancer incidence rate of 6.7 per 100 person-years, compared with 4.3 per 100 person-years among those without a significant decline.
After adjustment for relevant factors, a hemoglobin decrease of 2 g/dL or more was associated with a higher risk of newly diagnosed cancer, with an adjusted hazard ratio of 1.42 (95% CI: 1.10–1.97).
The findings indicate that an otherwise unexplained reduction in hemoglobin may provide a clinical signal of an underlying malignancy in some patients receiving oral anticoagulants.
Gastrointestinal Cancer Shows Strongest Association
The association between hemoglobin decline and cancer was particularly strong for gastrointestinal malignancies.
Patients with a hemoglobin decrease of at least 2 g/dL had a 78% higher risk of gastrointestinal cancer, with an adjusted hazard ratio of 1.78 (95% CI: 1.12–2.83).
According to the study findings, anticoagulation may reveal otherwise clinically silent bleeding associated with early lesions. Therefore, an unexplained fall in hemoglobin after initiation of oral anticoagulant therapy may require assessment for potential occult sources of blood loss.
Risk Higher in Certain Patient Groups
The association between hemoglobin decline and newly diagnosed cancer was significantly stronger among older patients, individuals with chronic kidney disease, and those receiving antiplatelet therapy concurrently.
The researchers reported significant interactions for these patient characteristics, with P values for interaction below 0.05.
These findings suggest that the clinical significance of a hemoglobin decline may vary according to a patient’s age, underlying conditions, and concurrent medications.
Hemoglobin Decline Also Linked to Mortality and Major Bleeding
Beyond cancer incidence, subclinical reductions in hemoglobin were independently associated with increased all-cause mortality and a higher risk of subsequent major bleeding events.
However, the study found no significant differences between the groups in stroke or thromboembolic outcomes.
The findings highlight the importance of monitoring hemoglobin levels in patients with atrial fibrillation receiving oral anticoagulants, particularly when the decline occurs without an obvious clinical source of bleeding.
Clinical Significance of Unexplained Anemia
An asymptomatic hemoglobin reduction of 2 g/dL or more following initiation of oral anticoagulation may serve as a marker of previously undetected malignancy, particularly gastrointestinal cancer.
While the findings do not establish that anticoagulant therapy itself causes cancer, they suggest that an otherwise unexplained hemoglobin decline may warrant further investigation for occult bleeding or underlying disease.
Regular laboratory monitoring and appropriate clinical evaluation may therefore help identify potentially significant conditions at an earlier stage in selected patients receiving oral anticoagulation.
Important Highlights
- A hemoglobin decline of 2 g/dL or more after starting oral anticoagulation was associated with a higher risk of newly diagnosed cancer.
- The study included 6,789 patients with atrial fibrillation from the Korean National Health Insurance Service database.
- Gastrointestinal cancers showed the strongest association, with a 78% higher risk among patients with significant hemoglobin decline.
- Older patients, those with chronic kidney disease, and patients receiving antiplatelet therapy had stronger associations between hemoglobin decline and cancer.
- Subclinical hemoglobin reduction was also associated with higher all-cause mortality and future major bleeding.
- No significant differences were observed in stroke or thromboembolic outcomes between the groups.
